CLRB Cellectar Biosciences, Inc.

Nasdaq cellectar.com


$ 2.91 $ -0.63 (-18 %)    

Thursday, 13-Nov-2025 18:46:46 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 2.87
$ 3.48
$ 2.86 x 30
$ 3.20 x 100
-- - --
$ 2.86 - $ 63.30
201,977
na
12.17M
$ 1.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-18-2024 09-30-2024 10-Q
6 10-29-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-14-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-05-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-21-2022 12-31-2021 10-K
17 11-08-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-02-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-09-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-12-2019 06-30-2019 10-Q
27 05-06-2019 03-31-2019 10-Q
28 02-26-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-10-2018 06-30-2018 10-Q
31 05-11-2018 03-31-2018 10-Q
32 03-21-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-11-2017 03-31-2017 10-Q
36 03-15-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-11-2016 06-30-2016 10-Q
39 05-12-2016 03-31-2016 10-Q
40 03-11-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cellectar-biosciences-q3-eps-141-beats-253-estimate

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of...

 cellectar-biosciences-presented-preclinical-data-on-clr-121225-a-novel-actinium-based-alpha-emitter-for-pancreatic-ductal-adenocarcinoma-which-has-completed-ind-enabling-studies-and-may-advance-to-a-phase-1-trial

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develop...

 cellectar-eyes-2027-eu-launch-as-ema-backs-conditional-approval-path-for-its-blood-cancer-drug

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develop...

 evestia-to-provide-cellectar-with-full-cro-services-for-upcoming-phase-1b-study-evaluating-clr-125-for-treatment-of-triple-negative-breast-cancer

Cellectar Biosciences, Inc. ("Cellectar") (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the...

 cellectar-biosciences-to-present-preclinical-data-on-novel-pancreatic-cancer-therapy-at-aacr-conference

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develo...

 cellectar-to-present-interim-phase-1b-data-on-iopofosine-in-pediatric-brain-cancer-at-aacr-conference

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and develop...

 cellectar-biosciences-q2-eps-339-beats-398-estimate

Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(3.39) per share which beat the analyst consensus estimate of...

 cellectar-biosciences-has-been-granted-european-patent-number-ep3773544-titled-phospholipid-flavagline-conjugates-and-methods-of-using-the-same-for-targeted-cancer-therapy

https://data.epo.org/publication-server/publications/pdf?path=2025/30/DOC/EPNWB1/EP19784548NWB1/EP19784548NWB1.pdf

 cellectar-biosciences-prices-6m-offering-of-865k-class-a-units-and-335k-class-b-units-with-warrants-exercisable-at-525-price-per-class-a-unit-is-500-and-the-price-per-class-b-unit-is-499999

Cellectar Biosciences, Inc.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION